Cancer Treatment Impacted by Drug Shortage in India — Full Report

A shortage of essential chemotherapy drugs, Cisplatin and Carboplatin, is impacting cancer treatment across India. These drugs, widely used in the treatment of lung, oral, cervical, uterine, ovarian, and testicular cancers, have been in short supply for the past two to three weeks. Experts, including Dr. Shyam Aggarwal of Delhi's Sir Ganga Ram Hospital, have highlighted the severity of the situation, with approximately 70% of cancer patients potentially affected.

Dr. Hardeep Kaur from Jawaharlal Nehru Cancer Hospital stated that many patients are unable to receive complete treatment due to the unavailability of these drugs. Some are being sent home without treatment, disrupting the continuity and effectiveness of care. Similarly, Dr. T.P. Sahu from Bhopal expressed concern over the inability to provide standard treatment protocols, emphasizing the critical nature of the shortage.

The shortage has also led to changes in treatment approaches, according to Dr. Tushar Palve from Mumbai's KEM Hospital. While alternative chemotherapy drugs are available, the absence of platinum-based drugs is affecting specific patient groups. Domestic pharmaceutical companies have been urged to increase production to address the supply gap.

The Indian government has approved a price increase for Cisplatin and Carboplatin, with potential hikes of 10% to 50%, to ensure continued production and availability. Rising raw material costs and global supply chain disruptions have contributed to the crisis. These drugs, listed under the National Essential Medicines List (NLEM), are crucial for cancer treatment, particularly for patients from lower-income groups.

Key Points
- India faces a shortage of Cisplatin and Carboplatin, key chemotherapy drugs for cancer treatment.
- Approximately 70% of cancer patients may be affected by the shortage, according to experts.
- Rising production costs and supply chain disruptions are cited as reasons for the crisis.
- The government has approved a price increase to ensure continued availability of these drugs.
- Doctors are adapting treatment protocols due to the unavailability of platinum-based chemotherapy drugs.